For example, everolimus, an inhibitor of mTOR, in combination with exemestane and ribociclib has shown efficacy for the treatment of advanced ER+ HER2 negative breast cancer after progression on treatment with CDK4/6i (215, 216). Here, ERBB2 is linked to breast carcinoma.